Please login to the form below

Not currently logged in
Email:
Password:

Icon appoints Allergan’s Ira Spector

He also has 17 years’ experience at Wyeth
icon ira spector

Dr Ira Spector has left his senior role at Allergan to join the clinical research organisation (CRO) Icon as executive VP, analytics and consulting.

Dr Spector was most recently senior VP of global development operations at Allergan where he spent four years. Prior to this he spent 17 years at Wyeth, leaving shortly after the company's takeover by Pfizer.

In his new role at Icon Dr Spector will lead the company's global consulting and drug development services and will also be responsible for Icon's business process improvement and analytics capabilities.

Icon's chief operating officer Dr Steve Cutler commented on the new appointment: “His extensive experience in managing some of the world's largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers' drug and device programmes.”

10th September 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics